Adapting stainless steel facilities to incorporate increased use of disposable technology can help reduce costs and improve quality compliance, say TFS and Lonza.
Genesis Biopharma has merged with Lion Biotechnologies and says its tumor-infiltrating lymphocyte (TIL) technology can offer higher potency cancer drugs with lower manufacturing costs.
The US National Institutes of Health (NIH) announced this week that the famous HeLa genomic sequence data will continue to be available for scientists worldwide, though they will have to apply for access to the data.
inVentiv Health and Oncobiologics are employing a unique risk-sharing partnership to bring a number of the biggest blockbuster biologics to market as biosimilars.
Lonza has granted access to its potency boosting expression system to antibody developer Sorrento Therapeutics just days after a signing a similar deal with Pfizer.
GlaxoSmithKline says MAbs (monoclonal antibodies) will play an important part in its future pipeline as it licenses and internalizes a discovery tech platform from Adimab.
Piramal is upgrading its ADC (antibody drug conjugate) manufacturing capacity in response to demand from clients in late phase trials looking to ramp up production.
New heat stabilization technology can preserve the quality of tissue samples used in mass spectrometry imaging to improve the accuracy of downstream analytical results.
Making better CHO cell lines for biomanufacturing may soon be a more precise task according to the team behind the draft Chinese hamster genome published last week.
A new genetically modified strain of E. Coli cells could create enough protein for downstream production without the need for the challenging endotoxin removal steps that are currently employed.
Recent reports of a 'clinical trial' assessing 'stem cells' for the treatment of AMD are wrong say the Japanese researchers trying to transform somatic cells into retinal pigment epithelium (RPE) cells for transplant.
Harbour Antibodies has received a double boost this week raising $3.3m (€2.5m) for its transgenic H2L2 mice technology and adding Pfizer to its list of clients.
AB Sciex is combining its chromatography business with the capillary electrophoresis (CE) business from Beckman Coulter (BC) to align BC’s expertise in microscale separation with AB’s expertise in microfluidics.
Quality concerns and high shipping costs mean BioPharmas currently prefer Western CMOs, but improving standards and market opportunities may soon make Chinese contractors more attractive, experts say.
Stem cell therapeutics firm ReNeuron will conduct clinical development and – eventually – manufacturing at a new UK base in Wales in a move facilitated by Arthurian Life Sciences.
Europe may soon approve the first biologic made according to quality by design (QbD) principles, but opinions are still split over whether the approach should even be applied to biopharmaceuticals.
Industry has been slow to implement single-use technologies for microbial cultivations, according to Sartorius which has launched a new bioreactor gas sensor.
With the Chinese NAP (nucleic acid purification) market expected to grow more than 8% over the next year and no clear market leaders, companies are looking to take control of the industry space.
Biopharma firms, particularly those producing insulin and five of its analogues, have another option in the market of sub-2 micron solid-core chromatography columns with a recent offering from Waters.
As biopharma manufacturers look to save money setting up facilities and cleaning equipment, companies are increasingly turning to single-use technology and especially single-use bioreactors.
Could a genetically engineered adenovirus really spark a simian revolution and make chimps our masters? BioPharma-Reporter.com looks at the ‘science’ of the 2011 movie “Rise of the Planet of the Apes.”
The European Medicine’s Agency (EMA) has approved the first biosimilar monoclonal antibodies and expects to approve increasingly complex biosimilars as the regulatory framework becomes more flexible.
Keeping up with the latest technology news is a must for biomanufacturers according to an MIT Professor who told BioPharma-Reporter.com new advances in microtechnologies could help address process development challenges.
After patent expiration led to facility shuttering and cutbacks, Irish manufacturing will receive a $130m (€100m) boost to prepare for Pfizer’s new pipeline, the company says.
Primate research is still vital to drug development say CROs after US NIH announces plan to reduce the number of chimps it uses in preclinical testing.
Aesica's new Technical Director talks CMO flexibility and Catalent appoints new delivery unit head - welcome to Outsourcing-Pharma's People on the Move.
US scientists claim their combination of a novel nanoparticle production platform and innovative spray coating technology paves the way for improved drug, biologic and vaccine targeting.
Avanir Pharmaceuticals has bought North American rights to OptiNose’s novel intranasal delivery system to treat acute migraines, which is expected to be filed for US FDA approval by early 2014.
A consortium of European vaccine experts, including the Swiss CRO Preclin Biosystems, has received almost €5.5m ($7.1m) from the EU to develop a vaccine against the deadly MRSA bacteria.
Critical Pharmaceuticals says its protein and peptide delivery technologies offer long acting injectables and greater compliance, saving money and easing patient administration.
In a momentous first for both countries, regulatory officials from China and Taiwan sat down at the same table on Tuesday and discussed their relatively similar ideas around the regulation of drug approvals.
BMS have appointed a new director and ex Shire-CEO joins Questcor - yes, you've guessed it, it's in-Pharmatechnologist.com's weekly pharma people round-up.
The Brazilian Government is to fund a new facility to produce the Protalix-Pfizer Gaucher's disease drug Uplyso as part of a supply and tech transfer deal worth $280m (€212m).
Phyton Biotech has received European approval for a version the cancer drug API docetaxel whose production does not rely on the scarce yew tree extract used in traditional manufacturing methods.
Ambrx and Zhejiang Medicine have selected Wuxi to accelerate the development of a potential ADC (antibody drug conjugate) targeting Her2-positive breast cancer.